Diabetes REduction Assessment with ramipril & rosiglitazone Medication (DREAM) study

Introduction

International (21 countries), multicenter (191 centers) randomized, double-blind, placebo-controlled trial

5269 patients with impaired glucose tolerance, or high fasting

serum glucose, without cardiovascular disease

Average age 55 years

Study medications:

• ramipril
• rosiglitazone

Endpoints:

• development of diabetes

Conclusions:

• treating 8 patients for 3 years with rosiglitazone 8 mg/day will prevent 1 case of diabetes
• ramipril 15 mg/day for 3 years does NOT prevent diabetes or mortality; there was a significant effect on regression to normoglycemia favoring ramipril

More general terms

• clinical trial

Additional terms

• Dutch Randomized Endovascular Aneurysm Management trial (DREAM trial)